Vascular aging
Conditions
Interventions
hUC-MSCs intervention group:Conventional drug therapy + hUC-MSCs
External control group 1- conventional treatment group:Conventional drug therapy
External control group 2- lifestyle group:Conventional medication + lifestyle intervention
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Age 60-80 years old; (2) Diagnosis: 1) Stable coronary artery disease: according to the diagnostic criteria of Chinese Guidelines for the Diagnosis and Treatment of stable coronary artery disease 2018, that is, chronic stable exertional angina, ischemic cardiomyopathy and stable disease after acute coronary syndrome; 2) old myocardial infarction: patients met the diagnostic criteria of the Guidelines for the Diagnosis and Treatment of Acute ST-segment elevation myocardial infarction with at least one coronary artery stenosis > 50%; 3) PWV > 1800. (3) Be able to cooperate with the completion of the assessment and follow-up; (4) Patients voluntarily participated in the study and provided written informed consent by themselves or their legal representatives. (5) Life expectancy over 12 months; (6) Not participating in other intervention studies during the same period.
Exclusion criteria
Exclusion criteria: (1) patients with severe cardiovascular diseases (such as unstable angina pectoris, myocardial infarction, severe heart failure, etc.); (2) patients with chronic wasting diseases such as severe liver and kidney insufficiency and malignant tumors; (3) patients with diseases affecting cognition (such as dementia); (4) stroke, uncontrolled hypertension or hyperglycemia; Drug or alcohol abuse; (5) patients with autoimmune diseases; Presence of active infection, including antibodies to hepatitis B, hepatitis C, or hepatitis C HIV antibody positive); (6) planned organ transplantation; (7) frailty caused by other diseases or in the acute stage of illness; (8) have allergic constitution or positive history of drug allergy, or have been clearly allergic to stem cells or related preparations; (9) there are other conditions that may affect physical health.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulse Wave Velocity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intima-media thickness of carotid and peripheral arteries, IMT;Adverse cardiovascular and cerebrovascular events, MACE;Interleukin, IL;High-sensitivity C-reactive protein, Hs-CRP;Nicotinamide adenine dinucleotide, NAD+;Endothelial cell microparticles, EMPs;B-type natriuretic peptide, BNP;Homocysteine, Hcy;Lymphocyte subpopulation;Vasodilatory function, FMD;The reactive hyperemia index, RHI;Ankle-brachial index, ABI;A 6-minute walk test was performed, 6MWT;SF-36;Mental state assessment scale, HAD;Blood pressure;Abdominal girth;Body mass index, BMI;Glycosylated hemoglobin, HbA1c; | — |
Countries
China
Contacts
Public ContactCao Feng
Chinese PLA General Hospital
Outcome results
None listed